ASIS for Enbrel in Plaque Psoriasis
Public ClinicalTrials.gov record NCT02112097. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
AUTOMATIC SUBDERMAL INJECTOR SYSTEM (ASIS) Corporation has developed and patented the only automatic injection system for delivery of injectable products to the optimum spot, just outside of the fascia, which exists subdermally (between the skin and muscle) or interfascial (between the deeper muscles). ASIS device creates that bloodless space, enhancing Enbrel's efficacy and preventing unnecessary distant spread and adverse reactions. This space remains bloodless as long as the skin is lifted up or filled with an injectable product. Although ASIS device was initially designed to best administer BOTOX for such muscular conditions as Upper limb Spasticity, Cervical Dystonia, Chronic Migraine, Strabismus, Blepharospasm, and Primary Axillary Hyperhidrosis, the technology will also benefit other injectable products, including: GAMMAGARD for Primary Immunodeficiency (PI) and Insulin for Diabetics, etc.
Study identification
- NCT ID
- NCT02112097
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 60 participants
Conditions and interventions
Conditions
Interventions
- Gadolinium Drug
- Efficacy of Enbrel subcutaneously at Week 12 Drug
- Efficacy of Enbrel subcutaneously at Week 24 Drug
- Efficacy of Enbrel subcutaneously at Week 36 Drug
- Efficacy of Enbrel subdermally at Week 12 Drug
- Efficacy of Enbrel subdermally at Week 24 Drug
- Efficacy of Enbrel subdermally at Week 36 Drug
- PASI 75 n(%) subcutaneously at Week 12 Drug
- PASI 75 n(%) subcutaneously at Week 24 Drug
- PASI 75 n(%) subcutaneously at Week 36 Drug
- PASI 75 n(%) subdermally at Week 12 Drug
- PASI 75 n(%) subdermally at Week 24 Drug
- PASI 75 n(%) subdermally at Week 36 Drug
- Adverse Reactions of Enbrel subcutaneously Drug
- Adverse Reactions of Enbrel subdermally at Week 36 Drug
Drug
Eligibility (public fields only)
- Age range
- 21 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2015
- Primary completion
- May 31, 2016
- Completion
- May 31, 2017
- Last update posted
- Jun 23, 2015
2016 – 2017
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Automatic Subdermal Injector System, Inc | Westminster | California | 92683 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02112097, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 23, 2015 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02112097 live on ClinicalTrials.gov.